Article
BioNTech's OncoC4 partnership off to good start with mid-stage trial results
Rating:
0.0
Views:
41
Likes:
1
Library:
1
BioNTech said on Friday that a new cancer immunotherapy candidate that it is working on with U.S. partner OncoC4 Inc was shown to shrink tumours in close to 30% of participants in a mid-stage lung cancer trial.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value